Your email has been successfully added to our mailing list.

×
-0.0285714285714284 -0.017142857142857 -0.0164999999999999 -0.0714285714285713 -0.0678571428571427 -0.133964285714286 -0.114285714285714 -0.117857142857143
Stock impact report

OncoMed Provides Update on Navicixizumab Partnership

ONCOMED PHARMACEUTICALS (OMED) 
Last oncomed pharmaceuticals earnings: 11/1 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: oncomed.com/invest/index.cfm
Company Research Source: GlobeNewswire
REDWOOD CITY, Calif., Sept. 20, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that Celgene has notified OncoMed that due to strategic product portfolio considerations Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83). Celgene continues to retain its options to license OncoMed’s etigilimab (anti-TIGIT monoclonal antibody, OMP-313M32) and rosmantuzumab (anti-RSPO3, OMP-131R10) under the collaboration. OncoMed and Celgene are working to formalize the termination of the collaboration agreement with respect to navicixizumab, and OncoMed expects to retain worldwide rights to navicixizumab. “While we are disappointed in Celgene’s decision, we thank them for the productive interactions in evaluating navicixizumab, and we respect their decision given Show less Read more
Impact Snapshot
Event Time:
OMED
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for OMED alerts
Opt-in for
OMED alerts

from News Quantified
Opt-in for
OMED alerts

from News Quantified